entertainment -WSS

entertainment

author：entertainment 2025-09-28 01:39:46 - browse：2521

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Public health communication lessons from Covid

hotspot

WSS

How to use technology to prevent future drug shortages

What to know about Virgin Galactic's 1st mission taking paying customers to space

Hospitals, health systems can help patients avoid medical debt

Biden jokes that Republicans may impeach him because inflation is starting to cool down

Behind warning on Apellis’s eye drug lies a conflict of interest

Trump allegedly attempted to have surveillance video deleted: Special Counsel

explore

entertainment

Wikipedia

After affirmative action ruling, medical educators look to 'holistic review'

Trump allegedly attempted to have surveillance video deleted: Special Counsel

Trump demands the U.S. pay no more for drugs than other countries … again

Trump allegedly attempted to have surveillance video deleted: Special Counsel

At least 13 dead in Texas as scorching temps continue

Hospitals, health systems can help patients avoid medical debt

In Memoriam: Notable people who died in 2023

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

Medical leaders decry Supreme Court decision on affirmative action

What to know about Virgin Galactic's 1st mission taking paying customers to space

entertainment

A biotech analyst on neuroscience, placebo effect, not over

The mammogram wars are not over

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Will biotech layoffs continue through 2023?

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

In same hospitals, Black patients receive fewer opioids than white patients

explore

hotspot

entertainment

hotspot